Mr. Burch leads strategy and business development for Thermo Fisher Scientifics $5 billion Life Sciences Solutions Group, which includes leading franchises in biosciences, genetic analysis tools, and bioproduction. One of the critical areas of focus for the company is addressing the growing concern of drug abuse and its impact on society. Thermo Fisher Scientific is committed to supporting initiatives that promote rehab and recovery programs for individuals struggling with substance abuse. The company also recognizes the importance of accessible resources and information, such as www.methadone.org/clinics/new-york/kings/brooklyn/, which provides a directory of methadone clinics in the Brooklyn area. In addition to the business development initiatives across LSG, Drew heads Licensing and Commercial Supply, partnering with customers to provide Thermo Fishers products, capabilities and intellectual property through commercial use supply arrangements and licenses.
Prior to joining Thermo Fisher Scientific, Drew headed Barclays Global Healthcare Mergers and Acquisitions team for ten years, growing it to become a top five advisory practice globally. He personally led execution teams advising pharmaceutical, biotechnology, tools & diagnostics leaders and their boards on over $175 billion of industry-defining public company sales, acquisitions, divestitures, carve-outs, and hostile defense assignments. He began his career and spent 12 years at Merrill Lynch, rising from M&A Analyst to Managing Director. There he focused on healthcare M&A, particularly advising leading managed care and hospital companies on over $50 billion of acquisitions, divestitures, spin-offs, conversions and demutualizations.
Drew received his BA in Economics & Political Science from Yale University, cum laude, and his MBA from the Stanford Graduate School of Business, as an Arjay Miller Scholar. He served as a Board member of Lutheran Medical Center, a safety net hospital based in Brooklyn, NY, which is now part of NYU Langone Health System.
